Year-end Report January - December 2021
October – December 2021 · Net sales rose by 112% to SEK 42,060 (19,850) thousand. About SEK 20 million relates to licensing agreements with Selecta Bioscience. Growth is 108%, adjusted for currency effects. · Gross profit rose by 97% to SEK 39,024 (19,761) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 23,361 (6,196) thousand. · Operating profit jumped SEK 17,291 thousand and totaled SEK 21,895 (4,604) thousand. · Comprehensive income for the period improved by SEK 16,828 thousand and totaled SEK 23,175 (6,347) thousand. ·